Knowledge Hub

A Comparison of Moxifloxacin-Induced QTcH Prolongation in Two Species via the Evaluation of Minimum Detectable Difference
2025 American College of Toxicology Meeting – Phoenix, Arizona

ALG-801 Demonstrates Superior Therapeutic Efficacy in Sugen-Hypoxia Model of Pulmonary Hypertension
2025 European Respiratory Society Meeting – Amsterdam, Netherlands

Evaluation of Minimum Detectable Difference via Moxifloxacin-Induced QTcH Prolongation
2025 Society of Toxicology Meeting – Orlando, Florida

Serum Glucocorticoid Regulated Kinase 1 (SGK1) Inhibitor Reduced Hypertension in a Salt-Sensitive Model of Heart Failure with Preserved Ejection Fraction
2024 American Heart Association Meeting – Chicago, Illinois

Attenuation of Drug-Induced QT-Prolongation in Isolated Heart and Anesthetized Models of Drug-Induced QT Prolongation by Serum/Glucocorticoid Regulated Kinase 1 (SGK-1) Inhibitors
2024 Heart Rhythm Society Meeting – Boston, Massachusetts

Right Ventricular Function Evaluation by Echocardiography in a Pulmonary Arterial Hypertension Model
2023 Keystone Symposia Meeting – Santa Fe, New Mexico

Structural and Functional Changes of the Right Ventricle in Preclinical Models of Pulmonary Arterial Hypertension
2022 American Heart Association Meeting – Chicago, Illinois

Longitudinal Analysis Supports Reproducibility of Treatment with Sildenafil in a Pulmonary Arterial Hypertension Model
2021 American Heart Association Meeting – Boston, Massachusetts

Angiotensin-Converting Enzyme Inhibition in a Preclinical Model of Transverse Aortic Constriction with Reduced Variability of the Aortic Peak Pressure Gradient
2021 Experimental Biology Meeting – Virtual Meeting

Validation of The Use of a Telemetry Study to Measure Hemodynamic, Electrocardiographic and Respiratory Parameters in Conscious Models
2020 American College of Toxicology Meeting – Austin, Texas

APD588, a Novel, Selective S1P Receptor Modular, Regulates Inflammatory Responses and Attenuates Cardiac Dysfunction Following Experimental Myocardial Infarction
2020 American Heart Association Meeting – Virtual Meeting

Method of Transverse Aortic Constriction with Reduced Variability of the Aortic Peak Pressure Gradient
2020 Safety Pharmacology Society Meeting – Virtual Meeting

Sildenafil versus Ambrisentan in a Pulmonary Arterial Hypertension Model
2019 American College of Toxicology Meeting – Phoenix, Arizona

Effect of TSN3015 on the Development of Pulmonary Hypertension in Preclinical Models
2019 German PharmTox Meeting – Stuttgart, Germany

Effect of TSN3015 on the Development of Pulmonary Hypertension in Preclinical Models
2018 Safety Pharmacology Society Meeting – Washington DC, USA

Effect of Anesthetics on Hemodynamics in Pulmonary Hypertension Models
2016 Safety Pharmacology Society Meeting – Vancouver, Canada

Ferric Chloride-Induced Arterial Thrombosis Model in Preclinical Drug Development
2016 Safety Pharmacology Society Meeting – Vancouver, Canada

Differential Effect of Anesthetic on QT Interval Measurements – Part 2
2015 Society of Toxicology Meeting – San Diego, California

Effect of Anesthetic on QT Interval Measurements
2014 Society of Toxicology Meeting – Phoenix, Arizona

PAH Induced by Semaxanib and Low Oxygen Environment: Time Course Pulmonary Artery Pressure Increases Measured by Telemetry
2013 American College of Toxicology Meeting – San Antonio, Texas)

Veropaque, A Novel Contrast Formulation, Mitigates Contrast Induced Acute Kidney Injury
2012 Transcatheter Cardiovascular Therapeutics Meeting – Miami, Florida

Bosentan and Sildenafil Reduce PAH Induced by Semaxanib and Low Oxygen Environment
2012 Experimental Biology Meeting – San Diego, California

Bosentan and Sildenafil Reduce Pulmonary Arterial Hypertension Induced by Semaxanib and a Low Oxygen Environment
2012 Experimental Biology Meeting – San Diego, California

Dronedarone Effects on Atrial and Ventricular Electrophysiology in Conscious Models
2012 Experimental Biology Meeting – San Diego, California

Effect of Pacing Rate and Blockade on Cardiac Refractory and His-Bundle Conduction
2008 Safety Pharmacology Society Meeting – Madison, Wisconsin

Subcutaneous Therapy for Portal Hypertension: PHIN-214, A Partial Vasopressin Receptor 1A Agonist

Data for PharmaIN was published in Biomedicine and Pharmacotherapy, assessing the use of PHIN-214 as a novel therapeutic in the treatment of portal hypertension. Our labs used bile duct ligation in the rat along with continuous telemetry of portal venous pressure to support the potential of PHIN-214 as a novel drug candidate in this area.

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Pulmonary Arterial Hypertension Model

In preclinical studies, the monocrotaline (MCT) injury model in rats is widely used to evaluate drug efficacy for treating PAH. This protocol describes the echocardiographic evaluation of the RV in naïve and MCT-induced PAH rats.

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan

Data for Eli Lilly/CoLucid was published in the British Journal of Pharmacology that assessed the in vivo vascular effects of lasmitidan compared to sumatriptan. Sonomicrometry was used to determine carotid and coronary arterial diameter, along with vasoconstriction and vasodilation.

Preclinical Studies of a Kidney Safe Iodinated Contrast Agent

In an attempt to develop a contrast agent that is less damaging to the kidneys, we have studied the effects of adding a small amount of the substituted cyclodextrin, sulfobutyl-ether-β-cyclodextrin (SBECD), to iohexol in preclinical models of renal toxicity.

PM101: A Cyclodextrin-Based Intravenous Formulation of Amiodarone Devoid of Adverse Hemodynamic Effects

This study provides a useful model for the continued search for a safe and effective intravenous amiodarone formulation devoid of the hypotensive risk associated with the current commercial formulation.

Comparison of the Cardiac Electrophysiology and General Toxicology of Two Formulations of Intravenous Amiodarone

Intravenous amiodarone (AIV) must be administered slowly after dilution to avoid hypotension, which is due to the cosolvents polysorbate 80 and benzyl alcohol used in its formulation. PM101 is a formulation of amiodarone devoid of these cosolvents, which enables bolus administration. We evaluated any potential toxicity or exaggerated adverse cardiac electrophysiologic effects of PM101 compared with AIV and control.

The Hypotensive Effect of Intravenous Amiodarone is Sustained Throughout the Maintenance Infusion Period

The objective of the present study was to determine whether the maintenance dose of the conventional formulation of intravenous amiodarone was associated with sustained hypotension throughout the dosing period.

Advantages of the Perfused Isolated Heart for the Assessment of the Electrophysiologic and Hemodynamic Effects of Drug Candidates

This paradigm acts as a physiologically relevant bridge between purely in vitro assays and costly, resource-intensive whole-animal studies. The model has been used extensively in experimental cardiovascular investigations and it is a widely accepted surrogate for the study of human cardiac function.

A nephroprotective iodinated contrast agent with cardioprotective properties: A pilot study

Neurrow Pharmaceuticals conducted a pilot study examining the putative anti-ischemic effect of Captisol Enabled-iohexol in myocardial infarction. Early data are suggesting this formulation is superior to iohexol alone with regard to preservation of cardiomyocyte integrity and preservation of cardiac function.

Mesenchymal Stromal Cell-Derived Exosomes Improve Mitochondrial Health in Pulmonary Arterial Hypertension

We performed studies for United Therapeutics to determine whether the administration of mesenchymal stromal cell-derived exosomes could improve PAH in both mice and rats. Using both hypoxia alone and hypoxia/Sugen models, our data demonstrated improvements in both pulmonary hemodynamics and right ventricular hypertrophy after exosome administration.

Sotatercept (ACTRIIA-Fc) Rebalances BMP and Activin/TGF-β Signaling to Attenuate Pulmonary Hypertension

Acceleron Pharma enlisted CorDynamics to study the effects of RAP-011, a murine analog of Sotatercept, compared to sildenafil in both the monocrotaline and hypoxia-sugen models of pulmonary arterial hypertension. Note the large reductions in both mean pulmonary arterial pressure and right ventricular hypertrophy with RAP-011.

Effect of XEN-R0703 on Inducibility and Atrial Refractoriness in a Chronic Model of Atrial Fibrillation

We generated data for Xention that showed notable efficacy of XEN-R0703 with regard to increasing atrial refractoriness and reduction of atrial fibrillation inducibility in a chronic, conscious model of AF. XEN-R0703 also did not affect corrected QT interval, an indication of atrial vs. ventricular selectivity.

Lasmiditan and Sumatriptan Comparison of In Vivo Vascular Constriction and In Vitro Contraction of Human Arteries

Working with CoLucid Pharmaceuticals, CorDynamics studied the vascular properties of lasmitidan and sumatriptan in preclinical cardiovascular studies and compared these results with human isolated arteries. The lack of vasoconstrictive properties of lasmitidan may be a cardiovascular safety advantage compared to the triptans.

Investigation of Mechanism of Drug-Induced Cardiac Injury and Torsades de Pointes

In collaboration with Hoffman-La Roche, CorDynamics conducted studies to determine the molecular mechanism of an arrhythmia found during the course of routine toxicological assessments. The compound RO5657, a CCR5 antagonist, was discovered to have the rare liability of inducing torsades de pointes (polymorphic ventricular arrhythmia) in normal, healthy animals.

Pharmacological Characterization of KLYP961, A Dual Inhibitor of Inducible and Neuronal Nitric Oxide Synthases

CorDynamics collaborated with the Kalypsys study of KLYP961. KLYP961 represents an ideal tool with which to probe the physiological role of NO derived from iNOS and nNOS in human pain and inflammatory states. KLYP961 has minimal off-target activity, desirable drug like properties such as pharmacokinetic profile, CYP-450 and hERG activities. In addition, KLYP961 has efficacy in a range of pain/inflammation models both in rodents and non-human primates.

Monocrotaline Induced Pulmonary Arterial Hypertension

In collaboration with Corridor Pharmaceuticals, CorDynamics demonstrated the novel serotonin receptor antagonist C-122 prevents monocrotaline induced pulmonary arterial hypertension in rats in a paper published in the European Journal of Pharmacology. The authors hypothesized that interfering with serotonin function may reduce the vascular remodeling and hemodynamic changes that occur in this preclinical model.

A Small-Molecule Antagonist of HIF2a Is Efficacious in Preclinical Models of Renal Cell Carcinoma

CorDynamics conducted studies for Peloton Therapeutics using rat telemetry to examine the cardiovascular effects of a small-molecule HIF2a antagonist, PT2385. In addition, the increased blood pressure following administration of the VEGF receptor antagonist sunitinib was detailed.

Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation

In collaboration with Novartis Pharmaceuticals, CorDynamics demonstrated the differential effects of Englerin A and B in an anesthetized rat model of cardiovascular assessment.

Oncolytic peptides DTT‐205 and DTT‐304 induce complete regression and protective immune response in experimental colorectal cancer

Working with Lytix Biopharma, CorDynamics used telemetered rats to investigate the potential adverse effects of DTT-205 and DTT-304 – oncolytic peptides that represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities including colorectal cancer (CRC).

The Vascular Disrupting Agent STA-9584 Exhibits Potent Antitumor Activity by Selectively Targeting Microvasculature at Both the Center and Periphery of Tumors

CorDynamics conducted Langendorff isolated heart assessments along with telemetry in large species for Enanta Pharmaceuticals to interrogate the cardiovascular profile of STA-9584, a vascular disrupting agent.